Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routine clinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis.

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

MONDELLO, PATRIZIA
Primo
;
PITINI, Vincenzo;CUZZOCREA, Salvatore
Penultimo
;
2016-01-01

Abstract

Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routine clinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis.
2016
File in questo prodotto:
File Dimensione Formato  
The Oncologist-2016-Mondello-theoncologist.2016-0103.pdf

solo utenti autorizzati

Descrizione: Versione epub
Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 743.93 kB
Formato Adobe PDF
743.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
theoncologist.2016-0103.pdf

solo utenti autorizzati

Descrizione: Versione a stampa
Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 732.67 kB
Formato Adobe PDF
732.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3087895
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 0
social impact